Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Mitomycin
Therapeutic Area : Ophthalmology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Mobius Therapeutics™ Granted New US Patent for Injected Ophthalmic Mitomycin-C
Details : Mitosol (Mitomycin-C) is an antibiotic, isolated from the broth of Streptomyces verticillus Yingtanensis, intended for topical application to the surgical site of glaucoma filtration surgery.
Product Name : Mitosol
Product Type : Antibiotic
Upfront Cash : Inapplicable
March 01, 2023
Lead Product(s) : Mitomycin
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable